
Associate Professor David Croucher
Associate Professor David Croucher completed his undergraduate studies and PhD research at the University of Wollongong, followed by a post-doctoral position at the Garvan Institute of Medical Research, focusing on the functional characterisation of individual proteins in the behaviour of cancer cells. Pursuing the idea that these cancer-related proteins do not act in isolation, but are instead embedded within dynamic networks, David undertook a second post-doctoral position at Systems Biology Ireland in University College Dublin.
After establishing a research group at Systems Biology Ireland, David received a Future Research Leader grant from Cancer Institute NSW and returned to Garvan as head of the Network Biology group. His research group now focuses on combining computational modelling with novel proteomic and single-cell technologies to investigate how alterations in dynamic signalling networks can lead to tumour progression and therapeutic resistance.
Awards
- 2020
The Elaine Henry NBCF Fellowship
- 2017
Collaboration Achievement Award - Irish Laboratory Awards
- 2015
Young Garvan Award
- 2014
Future Research Leader Fellowship - Cancer Institute NSW
- 2012
Starting Investigator Research Grant - Science Foundation Ireland and Marie Curie Actions COFUND
- 2007
Cancer Institute Early Career Development Fellowship - Cancer Institute NSW
- 2006
Premiers Award for Outstanding Cancer Research Scholar - Cancer Institute NSW
- 2005
Cancer Institute Research Scholar Award - Cancer Institute NSW
Selected publications
See all publications- PUBLISHED 28 November 2025Science Advances
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma
- PUBLISHED 3 March 2023Science Advances
Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma
- PUBLISHED 9 June 2020ELife
Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma
- PUBLISHED 21 March 2019Breast Cancer Research : BCR
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer
- PUBLISHED 12 July 2016Science Signaling
Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers
